1. Arneric SP (1991): New nicotinic agonists and cerebral blood flow. In: Second International Springfield Alzheimer Symposium, Giacobini E and Becker R, eds., Boston: Birkhauser, pp. 386–394.
2. Arneric SP, Sullivan JP and Williams M (1995): Neuronal nicotinic acetylcholine receptors: novel targets for CNS therapeutics. In: Psychopharmacology: 4th Generation of Progress, Bloom FE and Kupfer DJ, eds. New York: Raven Press (In Press).
3. Arneric SP and Williams M (1994): Nicotinic agonists in Alzheimer’s disease: does the molecular diversity of nicotine receptors offer the opportunity for developing CNS selective cholinergic channel activators? In: Recent Advances In The Treatment Of Neurodegenerative Disorders and Cognitive Function, Int Acad Biomed Drug Res, Racagni G, Brunello N and Langer SZ, eds. Basel: Karger, Vol. 7 pp. 58–70.
4. Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes M, Cadman ED, Adams P, Garvey DS, Wasicak J and Williams M (1994): ABT-418: A novel cholinergic ligand with cognition enhancing and anxiolytic activities I. In vitro characterization. J Pharmacol Exp Ther 270: (In Press).
5. Brioni JD, O’Neill AB, Kim DJB, Decker MW, Sullivan JP and Arneric SP (1994a): Anxiolytic-like effects of the novel cholinergic channel activator, ABT-418. J Pharmacol Exp Ther (In Press).